Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company CorMedix has acquired exclusive worldwide rights to develop, manufacture and market Neutrolin from ND Partners.
Subscribe to our email newsletter
Neutrolin is a liquid that locks a patient’s central venous catheter (CVC) between hemodialysis (HD) sessions to keep it free of infection and clots.
Bruce Cooper, president and CEO of CorMedix, said: “We hope Neutrolin will be a paradigm-changing weapon in fighting one of the single greatest causes of morbidity and mortality among the 300,000 kidney failure patients in the US who undergo life-sustaining HD treatments.”